AUROBINDO

June 27, 2022

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 **Company Code No. 524804**

Dear Sir / Madam,

SUB: Warning letter- Noncompliance with SEBI (LODR) Regulations, 2015.

We have received a warning letter from Securities Exchange Board of India (SEBI) on June 24, 2022, a copy of which is enclosed. The letter is in regards to certain disclosures made by the Company on the ongoing USFDA audit of Company's Unit-1 and observations made by the USFDA between the period 2019 to 2022. The SEBI warning letter observes that the Company had disclosed very limited and restricted information and that the Company did not disclose the detailed reasons and also did not consider-the observations of USFDA as serious.

The Company is advised to ensure compliance with all applicable provisions of SEBI Regulations and to place this warning letter before its Board of Directors in ensuing Board Meeting. The Company is also instructed to disseminate this letter to the Stock Exchanges.

We request you to take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

Encl: SEBI warning letter dated June 24, 2022

भारतीय प्रतिभूति
और विनिमय बोर्ड
Securities and Exchange Board of India

GENERAL MANAGER
CORPORATION FINANCE DEPARTMENT
Supervision Enforcement and Compliance (SEC)-II

CFD/CMD2/SG/OW/26018/2022
June 24, 2022

Shri B Adi Reddy
Company Secretary and Compliance Officer
Aurobindo Pharma Limited,
Plot No.2, Maitrivihar, Ameerpet,
Hyderabad, Telangana, 500038,

Sub: Warning letter – Non Compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR Regulations)

1. This has reference to the disclosure dated November 10, 2021 and January 14, 2022 made by Aurobindo Pharma Limited ("APL/Company") under Regulation 30 of the SEBI LODR Regulations, 2015, to the Stock exchanges. The disclosure was related to the receipt of OAI (Official Action Indicated) & warning letter respectively from the United States Food and Drug Administration (USFDA) for Unit I, an API (Active Pharmaceutical Ingredients) manufacturing facility in Hyderabad, pursuant to an inspection carried out by the USFDA in August 2021.

2. APL vide corporate announcement dated November 10, 2021, informed about the communication received from USFDA classifying the inspection conducted by USFDA inspection team, at its Unit I between August 02 to August 12, 2021 as OAI. The company further stated that this classification will not affect the continuing commercial supplies to the US market from this facility. Subsequently, on January 14, 2022, APL disclosed that with regard to OAI classification of Unit I, Company had received a warning letter from the USFDA for the said unit.

3. Form the disclosures made by the company, it was observed that the company had disclosed very limited and restricted information. The only fact disclosed was that a warning letter was received from USFDA. The company did not disclose the details on the reason and the non-compliance/aberration observed, for which the warning was issued.

सेबी भवन, प्लॉट सं. सी 4-ए, "जी" ब्लॉक, बांद्रा-कुर्ला कॉम्प्लेक्स, बांद्रा (पूर्व), मुंबई - 400 051.
दूरभाष : 2644 9950 / 4045 9950 (आई.वी.आर.एस.), 2644 9000 / 4045 9000 फैक्स : 2644 9019 से 2644 9022 वेब : www.sebi.gov.in

SEBI Bhavan, Plot No. C4-A, "G" Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051.
Tel.: 2644 9950 / 4045 9950 (IVRS), 2644 9000 / 4045 9000 Fax : 2644 9019 to 2644 9022 Web : www.sebi.gov.in

4. The company, in its response to SEBI, submitted that the company had communicated about the observations issued by the USFDA in the investor's earning call on August 13, 2021 and that the transcript of the same was disclosed on the stock exchange platform.

5. The above response was examined and it was found that the information disclosed by APL during investor call was same as the disclosure made and did not provide any additional information beyond what was already disclosed.

6. The company further submitted to SEBI that the USFDA was not satisfied with the response of the company on two of the observations issued in the inspection by the USFDA, for which warning was issued in January 2022. These two observations issued were not considered serious by APL, as the company had already taken robust corrective actions to mitigate the risk. Further, the concerns raised by USFDA have already been adequately addressed and status of corrective actions being continuously updated to the USFDA.

7. APL's submission on not considering the warning as serious is not tenable. While the warning letter is available on the USFDA website, the company choose to make limited disclosure. Mere disclosure of the receipt of the USFDA warning letter is insufficient and an impediment to assess the current status.

8. Having regard to the above, the disclosure by the company is not in line with the Principles Governing Disclosures and obligations of listed entity viz. Regulation 4 (j) of LODR Regulations read with Regulation 30 of SEBI (LODR) Regulations, 2015, wherein emphasis is laid on adequate and timely disclosure of material information to recognized stock exchanges.

9. The aforesaid non-compliance is viewed seriously. You are hereby warned and advised to ensure compliance with all applicable provisions of SEBI Regulations. Any such aberration in future would be viewed seriously and appropriate action would be initiated.

10. You are also advised to place this letter before your Board of Directors in its next meeting and disseminate the same to the stock exchange(s). The stock exchanges are advised to take note of the contents of the letter.

Yours faithfully,

Surabhi Gupta

Copy to BSE and NSE (*via email*)